STIM — Neuronetics Balance Sheet
0.000.00%
- $92.46m
- $134.16m
- $74.89m
Annual balance sheet for Neuronetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 49 | 94.1 | 70.3 | 59.7 | 18.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 9.05 | 9.98 | 15.4 | 18.7 | 24.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 65 | 115 | 98.8 | 93.8 | 58.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.35 | 5.1 | 5.32 | 4.78 | 33.3 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 78.7 | 141 | 117 | 116 | 141 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13.7 | 15.7 | 33.2 | 19.8 | 31.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 53.2 | 56 | 59.8 | 81.6 | 113 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 25.5 | 85.2 | 57.1 | 34.2 | 27.7 |
| Total Liabilities & Shareholders' Equity | 78.7 | 141 | 117 | 116 | 141 |
| Total Common Shares Outstanding |